Biotechnology Business Key Publications in 2002

From MyBio

1. Surprise US election results may boost biotech. Fox JL. Nat Biotechnol. 2002 Dec;20(12):1176
2. Shares in the human genome-the future of patenting DNA. Thomas SM, Hopkins MM, Brady M. Nat Biotechnol. 2002 Dec;20(12):1185-8
3. Patent opportunities in bioinformatics. Rzucidlo EC, Nassif CL. Drug Discov Today. 2002 Nov 1;7(21):1081-2
4. When will the bear move on?: The current problems of the biotechnology industry are not solely a reflection of the whole market but are also caused by some specific problems Brower V. EMBO Rep. 2002 Nov;3(11):1015-7
5. Biotechs hold their own in shifting industry Mitchell P. Nat Biotechnol. 2002 Nov;20(11):1065-6
6. Is your biotech giving away the store? Jacobs T. Nat Biotechnol. 2002 Nov;20(11):1079
7. Companies struggle amid stock market gloom. Mitchell P. Nat Biotechnol. 2002 Oct;20(10):961-2
8. Biotech follows dot.com boom and bust Jacobs T. Nat Biotechnol. 2002 Oct;20(10):973
9. A general approach for determining when to patent, publish, or protect information as a trade secret. Daizadeh I, Miller D, Glowalla A, Leamer M, Nandi R, Numark CI. Nat Biotechnol. 2002 Oct;20(10):1053-1054
10. China: Stem cells rise in the East. Dennis C. Nature. 2002 Sep 26;419(6905):334-6
11. Genomics. After the gold rush: gene firms reinvent themselves. Gura T. Science. 2002 Sep 20;297(5589):1982-4
12. China's biotech is starting to bloom. Stipp D. Fortune. 2002 Sep 2;146(4):126-30, 132, 134
13. Biotech meets the investors. Berry S. Trends Biotechnol. 2002 Sep;20(9):370
14. Pfizer-Pharmacia merger bodes ill for biotech? Fletcher L. Nat Biotechnol. 2002 Sep; 20:857-858
15. Just mad about mAbs. Jacobs T. Nat Biotechnol. 2002 Sep; 20:869
16. The role of foreign worker scientists in the US biotechnology industry Sevier ED, Dahms AS. Nat Biotechnol. 2002 Sep; 20:955-956
17. Sunbaked biotechnology in Australia. Littlejohn T. Nat Biotechnol. 2002 Sep; 20:873-877
18. BIOMEDICAL SCIENCE: Can Money Turn Singapore Into a Biotech Juggernaut? Normile D. Science. 2002 Aug 30;297(5586):1470-3
19. Biotech stocks struggle as financial markets tumble. Mitchell P. Nat Biotechnol. 2002 Aug; 20: 755-756
20. A consumer charter for genomic services. Ledley F. Nat Biotechnol. 2002 Aug; 20: 767
21. Stock-picking warm up Jacobs T. Nat Biotechnol. 2002 Aug; 20: 771
22. Needed: models of biotechnology intellectual property Gold ER, Castle D, Cloutier LM, Daar AS, Smith PJ. Trends Biotechnol. 2002 Aug;20(8):327-9
23. Biotech firms spurn university site Dalton R. Nature. 2002 Jul 25;418(6896):355
24. A summer financial makeover Jacobs T. Nat Biotechnol. 2002 Jul;20(7):653
25. New SEC regulations could hinder biotech investment Bouchie A. Nat Biotechnol. 2002 Jul;20(7):639-40
26. First biotech drug to treat psoriasis. Mitchell P. Nat Biotechnol. 2002 Jul;20(7):640-1
27. Biotechnology: the next engine of growth for Taiwan's economy?: The Taiwanese government is investing heavily in biotech infrastructure and researchers in an effort to repeat the country's success with IT technologies. Harris S. EMBO Rep. 2002 Jul; 3: 598-600
28. Rubicon genomics, inc. Langmore JP. Pharmacogenomics. 2002 Jul;3(4):557-60
29. CuraGen Corporation Mansfield T, Vincent MR. Pharmacogenomics. 2002 Jul;3(4):551-4
30. Acceptable Intellectual Property. Hilgartner S. 2002 Jun 17; J Mol Biol. 319:943-946
31. HGS drug flop latest genomics setback. Reid B. Nat Biotechnol. 2002 Jun;20(6):533
32. Sense and antisense for investors. Jacobs T. Nat Biotechnol. 2002 Jun;20(6):543
33. Trademarks: The "misunderstood" intellectual property. Perry EL, McHugh MC. Nat Biotechnol. 2002 Jun;20(6):627-8
34. Can personalized drugs pay off? Stipp D. Fortune. 2002 May 13;145(10):168
35. Bioinformatics: the role and limitations of patents. Welch TJ. Drug Discov Today. 2002 May 6;7(11):S77-S82
36. Nontraditional publications and their effect on patentable inventions. Garabedian TE. Nat Biotechnol. 2002 Apr;20(4):401-2
37. Software firm falls victim to shifting bioinformatics needs Knight J. Nature. 2002 Mar 28;416(6879):357
38. Market opportunity in computational proteomics. Razvi E. Biotechniques. 2002 Mar;Suppl:54-8, 60-2
39. Genomics firm aims to fill Asian gene gap Cyranoski D. Nature. 2002 Mar 14;416(6877):115
40. How to publish DNA sequences with copyright protection. Stemmer WP. Nat Biotechnol. 2002 Mar;20(3):217
41. Great companies, bad stocks Jacobs T. Nat Biotechnol. 2002 Mar;20(3):219
42. Venter’s departure sees Celera seek therapies. Dennis C. Nature 2002 Jan 31;415:461
43. Licence and collaboration agreements: protecting your most valuable asset Duxbury P, Mellett D. Nat Biotechnol. 2002 Jan; 20:91-92
44. Shift anticipated in DNA microarray market. Bouchie A. Nat Biotechnol 2002 Jan; 20:8

-- From YF Leung with permission Jon R 17:21, 24 July 2006 (BST)